Latest Vestal Point Capital, LP Stock Portfolio
Vestal Point Capital, LP Performance:
2025 Q4: 13.54%YTD: 15.37%2024: -12.47%
Performance for 2025 Q4 is 13.54%, and YTD is 15.37%, and 2024 is -12.47%.
About Vestal Point Capital, LP and 13F Hedge Fund Stock Holdings
Vestal Point Capital, LP is a hedge fund based in New York, NY. On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Vestal Point Capital, LP reported an equity portfolio of $2.9 Billions as of 31 Dec, 2025.
The top stock holdings of Vestal Point Capital, LP are , ACLX, TERN. The fund has invested 8.7% of it's portfolio in ABIVAX SA and 6.5% of portfolio in ARCELLX INC.
The fund managers got completely rid off AMICUS THERAPEUTICS INC (FOLD), IONIS PHARMACEUTICALS INC (IONS) and BECTON DICKINSON & CO (BDX) stocks. They significantly reduced their stock positions in NUVALENT INC (NUVL), DYNE THERAPEUTICS INC (DYN) and BLACK DIAMOND THERAPEUTICS INC (BDTX). Vestal Point Capital, LP opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), MERCK & CO INC (MRK) and ARROWHEAD PHARMACEUTICALS INC (ARWR). The fund showed a lot of confidence in some stocks as they added substantially to BIOMARIN PHARMACEUTICAL INC (BMRN), ENLIVEN THERAPEUTICS INC and AGIOS PHARMACEUTICALS INC (AGIO).
The top stock holdings of Vestal Point Capital, LP are , ACLX, TERN. The fund has invested 8.7% of it's portfolio in ABIVAX SA and 6.5% of portfolio in ARCELLX INC.
The fund managers got completely rid off AMICUS THERAPEUTICS INC (FOLD), IONIS PHARMACEUTICALS INC (IONS) and BECTON DICKINSON & CO (BDX) stocks. They significantly reduced their stock positions in NUVALENT INC (NUVL), DYNE THERAPEUTICS INC (DYN) and BLACK DIAMOND THERAPEUTICS INC (BDTX). Vestal Point Capital, LP opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), MERCK & CO INC (MRK) and ARROWHEAD PHARMACEUTICALS INC (ARWR). The fund showed a lot of confidence in some stocks as they added substantially to BIOMARIN PHARMACEUTICAL INC (BMRN), ENLIVEN THERAPEUTICS INC and AGIOS PHARMACEUTICALS INC (AGIO).
Vestal Point Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Vestal Point Capital, LP made a return of 13.54% in the last quarter. In trailing 12 months, it's portfolio return was 15.37%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| terns pharmaceuticals inc | 181,800,000 |
| merck & co inc | 81,576,500 |
| arrowhead pharmaceuticals inc | 59,751,000 |
| olema pharmaceuticals inc | 41,250,000 |
| immunocore holdings plc | 20,305,400 |
| upstream bio inc | 19,548,000 |
| crescent biopharma inc | 17,790,000 |
| biocryst pharmaceuticals inc | 17,550,000 |
New stocks bought by Vestal Point Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| biomarin pharmaceutical inc | 261 |
| enliven therapeutics inc | 230 |
| engene holdings inc | 185 |
| alto neuroscience inc | 161 |
| agios pharmaceuticals inc | 155 |
| kalvista pharmaceuticals inc | 152 |
| taysha gene therapies inc | 150 |
| abbott laboratories | 140 |
Additions to existing portfolio by Vestal Point Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| nuvalent inc | -95.82 |
| dyne therapeutics inc | -95.68 |
| black diamond therapeutics inc | -84.32 |
| repligen corp | -79.25 |
| ascendis pharma a/s | -70.83 |
| savara inc | -60.00 |
| scholar rock holding corp | -53.33 |
| revolution medicines inc | -53.17 |
Vestal Point Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| applied therapeutics inc | -8,619,820 |
| amicus therapeutics inc | -76,830,000 |
| astria therapeutics inc | -36,079,700 |
| ventyx biosciences inc | -6,375,500 |
| dianthus therapeutics inc | -46,433,000 |
| ionis pharmaceuticals inc | -70,326,500 |
| pulmonx corp | -1,344,600 |
| crinetics pharmaceuticals inc | -31,237,500 |
Vestal Point Capital, LP got rid off the above stocks
Sector Distribution
Vestal Point Capital, LP has about 66.2% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 66.2 |
| Others | 33.8 |
Market Cap. Distribution
Vestal Point Capital, LP has about 23.9% of it's portfolio invested in the large-cap and mega-cap stocks.
- UNALLOCATED
- MID-CAP
- LARGE-CAP
- SMALL-CAP
- MEGA-CAP
| Category | % |
|---|---|
| UNALLOCATED | 33.8 |
| MID-CAP | 22.7 |
| LARGE-CAP | 20.9 |
| SMALL-CAP | 18.9 |
| MEGA-CAP | 3 |
Stocks belong to which Index?
About 47% of the stocks held by Vestal Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
- S&P 500
| Index | % |
|---|---|
| Others | 53 |
| RUSSELL 2000 | 36.9 |
| S&P 500 | 10.1 |
Vestal Point Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Vestal Point Capital, LP
Vestal Point Capital, LP has 75 stocks in it's portfolio. About 45.4% of the portfolio is in top 10 stocks. ACLX proved to be the most loss making stock for the portfolio. was the most profitable stock for Vestal Point Capital, LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABT | abbott laboratories | 2.56 | 600,000 | 75,174,000 | added | 140 | ||
| ACLX | arcellx inc | 6.48 | 2,925,000 | 190,710,000 | added | 134 | ||
| AGIO | agios pharmaceuticals inc | 0.30 | 325,000 | 8,846,500 | added | 155 | ||
| ALC | alcon ag | 2.96 | 1,105,000 | 87,085,000 | added | 0.45 | ||
| ALEC | alector inc | 0.04 | 755,000 | 1,177,800 | reduced | -22.96 | ||
| APLT | applied therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARQT | arcutis biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ARWR | arrowhead pharmaceuticals inc | 2.03 | 900,000 | 59,751,000 | new | |||
| ASND | ascendis pharma a/s | 1.27 | 175,000 | 37,317,000 | reduced | -70.83 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AXSM | axsome therapeutics inc | 1.30 | 210,000 | 38,354,400 | added | 40.00 | ||
| BCRX | biocryst pharmaceuticals inc | 0.60 | 2,250,000 | 17,550,000 | new | |||
| BDTX | black diamond therapeutics inc | 0.07 | 870,000 | 2,114,100 | reduced | -84.32 | ||
| BDX | becton dickinson & co | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIIB | biogen inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BLTE | belite bio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMRN | biomarin pharmaceutical inc | 6.06 | 3,000,000 | 178,290,000 | added | 261 | ||
| BMY | bristol-myers squibb co | 0.46 | 250,000 | 13,485,000 | new | |||
| BRKR | bruker corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CARA | tvardi therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||